Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Sep;78(3):696–702. doi: 10.1172/JCI112629

Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation.

M E Hemler, D Glass, J S Coblyn, J G Jacobson
PMCID: PMC423654  PMID: 3018043

Abstract

Lymphocytes from the synovial fluid of eight out of eight rheumatoid arthritis (RA) patients had elevated very late activation antigen-1 (VLA-1) expression (10-36% positive cells), whereas peripheral blood lymphocytes (PBL) from RA patients and healthy controls had low VLA-1 expression (0-6% positive cells). During 1-2 wk of in vitro culture, VLA-1 increased on synovial fluid cells but remained low on PBL. In comparison, the interleukin 2 receptor (IL-2 R) was less prominent than VLA-1 on fresh synovial fluid cells, did not increase on cultured synovial fluid T cells, but did increase greatly on cultured PBL. The mitogen PHA reversed or prevented the appearance of VLA-1+, IL-2 R- synovial fluid cells during in vitro culture, thus giving IL-2 R+, VLA-1- cells. These results emphasize that VLA-1+ SF cells are different from resting cells or IL-2 R+ activated PBL T cells, and VLA-1 on synovial fluid T cells may be incompatible with mitogen stimulation. In addition, the VLA-2 heterodimer (165,000/130,000 relative molecular mass [Mr]) was regulated opposite to the VLA-1 heterodimer (130,000/210,000 Mr) on synovial lymphocytes, and thus the VLA-1/VLA-2 ratio is another indicator of the stage of T cell activation.

Full text

PDF
696

Images in this article

698Image
on p.698
699Image
on p.699

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burmester G. R., Jahn B., Gramatzki M., Zacher J., Kalden J. R. Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro. J Immunol. 1984 Sep;133(3):1230–1234. [PubMed] [Google Scholar]
  2. Burmester G. R., Yu D. T., Irani A. M., Kunkel H. G., Winchester R. J. Ia+ T cells in synovial fluid and tissues of patients with rheumatoid arthritis. Arthritis Rheum. 1981 Nov;24(11):1370–1376. doi: 10.1002/art.1780241106. [DOI] [PubMed] [Google Scholar]
  3. Cotner T., Williams J. M., Christenson L., Shapiro H. M., Strom T. B., Strominger J. Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med. 1983 Feb 1;157(2):461–472. doi: 10.1084/jem.157.2.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davidson B. L., Faust J., Pessano S., Daniele R. P., Rovera G. Differentiation and activation phenotypes of lung T lymphocytes differ from those of circulating T lymphocytes. J Clin Invest. 1985 Jul;76(1):60–65. doi: 10.1172/JCI111977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fox R. I., Fong S., Sabharwal N., Carstens S. A., Kung P. C., Vaughan J. H. Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis. J Immunol. 1982 Jan;128(1):351–354. [PubMed] [Google Scholar]
  6. Fox R. I., Hueniken M., Fong S., Behar S., Royston I., Singhal S. K., Thompson L. A novel cell surface antigen (T305) found in increased frequency on acute leukemia cells and in autoimmune disease states. J Immunol. 1983 Aug;131(2):762–767. [PubMed] [Google Scholar]
  7. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  8. Grimm E. A., Robb R. J., Roth J. A., Neckers L. M., Lachman L. B., Wilson D. J., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med. 1983 Oct 1;158(4):1356–1361. doi: 10.1084/jem.158.4.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hafler D. A., Hemler M. E., Christenson L., Williams J. M., Shapiro H. M., Strom T. B., Strominger J. L., Weiner H. L. Investigation of in vivo activated T cells in multiple sclerosis and inflammatory central nervous system diseases. Clin Immunol Immunopathol. 1985 Nov;37(2):163–171. doi: 10.1016/0090-1229(85)90147-3. [DOI] [PubMed] [Google Scholar]
  10. Hemler M. E., Jacobson J. G., Brenner M. B., Mann D., Strominger J. L. VLA-1: a T cell surface antigen which defines a novel late stage of human T cell activation. Eur J Immunol. 1985 May;15(5):502–508. doi: 10.1002/eji.1830150515. [DOI] [PubMed] [Google Scholar]
  11. Hemler M. E., Jacobson J. G., Strominger J. L. Biochemical characterization of VLA-1 and VLA-2. Cell surface heterodimers on activated T cells. J Biol Chem. 1985 Dec 5;260(28):15246–15252. [PubMed] [Google Scholar]
  12. Hemler M. E., Malissen B., Rebai N., Liabeuf A., Mawas C., Kourilsky F. M., Strominger J. L. A 55,000 Mr surface antigen on activated human T lymphocytes defined by a monoclonal antibody. Hum Immunol. 1983 Oct;8(2):153–165. doi: 10.1016/0198-8859(83)90010-1. [DOI] [PubMed] [Google Scholar]
  13. Hemler M. E., Sanchez-Madrid F., Flotte T. J., Krensky A. M., Burakoff S. J., Bhan A. K., Springer T. A., Strominger J. L. Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: cell distribution and antigenic relation to components on resting cells and T cell lines. J Immunol. 1984 Jun;132(6):3011–3018. [PubMed] [Google Scholar]
  14. Hemler M. E., Ware C. F., Strominger J. L. Characterization of a novel differentiation antigen complex recognize by a monoclonal antibody (A-1A5): unique activation-specific molecular forms on stimulated T cells. J Immunol. 1983 Jul;131(1):334–340. [PubMed] [Google Scholar]
  15. Ivanyi L., Lehner T., Burry H. C. The response of synovial fluid lymphocytes to T and B stimulants in vitro. Immunology. 1973 Nov;25(5):905–908. [PMC free article] [PubMed] [Google Scholar]
  16. Kearney J. F., Radbruch A., Liesegang B., Rajewsky K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol. 1979 Oct;123(4):1548–1550. [PubMed] [Google Scholar]
  17. Klareskog L., Forsum U., Malmnäs Tjernlund U. K., Kabelitz D., Wigren A. Appearance of anti-HLA-DR-reactive cells in normal and rheumatoid synovial tissue. Scand J Immunol. 1981 Aug;14(2):183–192. doi: 10.1111/j.1365-3083.1981.tb00198.x. [DOI] [PubMed] [Google Scholar]
  18. Kluin-Nelemans H. C., van der Linden J. A., Gmelig Meyling F. H., Schuurman H. J. HLA-DR positive T lymphocytes in blood and synovial fluid in rheumatoid arthritis. J Rheumatol. 1984 Jun;11(3):272–276. [PubMed] [Google Scholar]
  19. Mier J. W., Gallo R. C. Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Natl Acad Sci U S A. 1980 Oct;77(10):6134–6138. doi: 10.1073/pnas.77.10.6134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  21. Silver R. M., Redelman D., Zvaifler N. J. Studies of rheumatoid synovial fluid lymphocytes. II. A comparison of their behavior with blood mononuclear cells in the autologous mixed lymphocyte reaction and response to TCGF. Clin Immunol Immunopathol. 1983 Apr;27(1):15–27. doi: 10.1016/0090-1229(83)90052-1. [DOI] [PubMed] [Google Scholar]
  22. Yu D. T., Winchester R. J., Fu S. M., Gibofsky A., Ko H. S., Kunkel H. G. Peripheral blood Ia-positive T cells. Increases in certain diseases and after immunization. J Exp Med. 1980 Jan 1;151(1):91–100. doi: 10.1084/jem.151.1.91. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES